학술논문
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Document Type
Article
Author
Ahn, I.E.; Walker, H.A.; Black, R.; Montegaard, J.; Jacobson, C.A.; Armand, P.; Ng, S.Y.; Crombie, J.; Fisher, D.C.; LaCasce, A.S.; Brown, J.R.; Davids, M.S.; Arnason, J.; Hochberg, E.P.; Takvorian, R.W.; Abramson, J.S.; Brander, D.M.; Ren, Y.; Zhou, Y.; Tyekucheva, S.; Alencar, A.; Shune, L.; Omaira, M.
Source
In: Blood Advances . (Blood Advances, 27 February 2024, 8(4):832-841)
Subject
Language
English
ISSN
24739537
24739529
24739529